JOHNSON & JOHNSON (JNJ): 10-Q filed April 23, 2025

AI analysis of the 10-Q that JOHNSON & JOHNSON filed with the U.S. SEC on April 23, 2025, grounded in the primary-source EDGAR filing.

• Talc Litigation Risk Remains Material: J&J has reserved only 33% of estimated talc exposure, signaling substantial contingent liability and elevated risk of future charges that could materially impact financial results.

• Hedging Activities Indicate Earnings Volatility: Significant derivative instruments across interest rate swaps and FX contracts suggest management is actively managing exposure to interest rate and currency fluctuations that could pressure profitability.

• Operational Stability Maintained: No segment restructuring or impairment charges in Q1 2025 across Innovative Medicine and MedTech divisions, though cautious tone suggests management is monitoring for potential headwinds.

Filing analysis — key questions

Answers are generated from this SEC filing and StockHuntr's analysis. Not investment advice.

What does JOHNSON & JOHNSON (JNJ)'s 10-Q filed April 23, 2025 say?

Quarterly Period Covered: First quarter of fiscal year 2025, ending March 30, 2025 (period from December 30, 2024 to March 30, 2025) Financial Statements Included: Unaudited consolidated financial statements comprising balance sheet, income statement, statement of comprehensive income, statement of cash flows, and statement of stockholders' equity for the quarter Debt Instruments Disclosed:…

Is JNJ's 10-Q bullish or bearish?

Our analysis rates this filing CAUTIOUS. Johnson & Johnson presents an elevated but manageable concern profile typical of a mature blue-chip pharmaceutical company navigating significant litigation exposure. The primary concern centers on talc-related contingent liabilities where only 33% of…

How concerning is JNJ's latest 10-Q?

Concern level: HIGH (6.2/10). Key factors: Talc litigation contingent liability accrued at only 33% of estimated exposure - indicates material unresolved legal risk with potential for significant future charges exceeding current reserves; High-severity litigation risk (severity 7/10) persists with uncertain outcomes and earnings volatility potential if settlements or verdicts exceed accruals;…

What are the main risks flagged in JNJ's 10-Q?

Notable risk changes: Talc litigation contingent liability explicitly quantified at 33% accrual rate - indicates J&J has reserved only partial estimated exposure, suggesting material unresolved legal risk with potential for future charges; Multiple derivative instruments and hedging relationships disclosed across interest rate swaps, foreign exchange contracts, and cross-currency swaps - reflects exposure to…

About this analysis

Primary source:
View this 10-Q on SEC EDGAR
Additional data:
Yahoo Finance (market data)
Method:
StockHuntr analyzes filings with AI — see our methodology.
Analysis as of:
April 23, 2025
Published by:
StockHuntr

For research and education only. Nothing here is investment advice.

📄

Fetching Filing from SEC

Downloading filing HTML from SEC.gov...

15% Complete
1
Fetch filing from SEC
2
Parse document sections
3
Fetch prior filing
4
Analyze risk factors
5
Analyze management sentiment
6
Extract financial metrics
7
Compare to analyst consensus
8
Run ML prediction model
9
Finalize analysis

Note: Analysis typically takes 30-60 seconds. We're fetching real SEC filing data and running AI analysis on the actual content.